EditorialOpen Access
China’s Pharmaceutical Ascent: Opportunity for Global Health, Test for US Leadership
Cureus · 17.03.2026
DOI: 10.7759/cureus.105407 ↗Kurz gefasst
Editorial in der Zeitschrift Cureus, erschienen am 17.03.2026. Verfasst von Arya Babul und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences, Society for Awareness of Neglected Diseases, Las Vegas, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
ai‑enabled drug discoverychina pharmaceutical innovationfda regulatory policyglobal drug developmentnmpaout‑licensingpharmaceutical regulationpublic health policyregulatory harmonizationus-china relationship
Autor:innen und Institutionen
- Biomedical Sciences, Society for Awareness of Neglected Diseases, Las Vegas, USA.
- Biomedical Sciences, West Career and Technical Academy, Las Vegas, USA.
- Drug Development, Tavolar LLC, Las Vegas, USA.
- Genomics, Chinese Academy of Tropical Agricultural Sciences, Sanya, CHN.
- Drug Development, Quadra Therapeutics, Las Vegas, USA.
Zitieren
APA
Babul, A., Mahdavi, P., Hussain, M., & Babul, N. (2026). China’s Pharmaceutical Ascent: Opportunity for Global Health, Test for US Leadership. Cureus. https://doi.org/10.7759/cureus.105407
Vancouver
Babul A, Mahdavi P, Hussain M, Babul N. China’s Pharmaceutical Ascent: Opportunity for Global Health, Test for US Leadership. Cureus. 2026. doi:10.7759/cureus.105407
BibTeX
@article{Babul2026,
author = {Babul, Arya and Mahdavi, Parisa and Hussain, Momina and Babul, Najib},
title = {China’s Pharmaceutical Ascent: Opportunity for Global Health, Test for US Leadership},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.105407}
}
EUVIMED